{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:55:00Z","timestamp":1791201300166,"version":"4.2.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5015,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1093\/annonc\/mdj138","type":"journal-article","created":{"date-parts":[[2006,1,17]],"date-time":"2006-01-17T22:27:54Z","timestamp":1137536874000},"page":"563-570","source":"Crossref","is-referenced-by-count":382,"title":["Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG"],"prefix":"10.1016","volume":"17","author":[{"given":"D.","family":"Schadendorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schuler-Thurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.O.","family":"Nestle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.-B.","family":"Br\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Rittgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Edler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zimpfer-Rechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kamarashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jonuleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"T\u00fcttenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Keikavoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"K\u00e4mpgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdj138_bb0010","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj138_bb0015","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","article-title":"Palliative treatment of disseminated malignant melanoma: a systemic review of 41 randomised clinical trials","volume":"4","author":"Eigentler","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdj138_bb0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00002371-200003000-00012","article-title":"Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma","volume":"23","author":"Scheibenbogen","year":"2000","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdj138_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","article-title":"Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma","volume":"4","author":"Rosenberg","year":"1998","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdj138_bb0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdj138_bb0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdj138_bb0040","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdj138_bb0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1172\/JCI6909","article-title":"Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells","volume":"104","author":"Dhodapkar","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdj138_bb0050","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells","volume":"96","author":"Brossart","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj138_bb0055","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20012100","article-title":"Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells","volume":"195","author":"Schuler-Thurner","year":"2002","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdj138_bb0060","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1081\/CNV-120025091","article-title":"The first 1000 dendritic cell vaccinees","volume":"21","author":"Ridgway","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdj138_bb0065","unstructured":"Dendreon Corporation. Dendreon's phase 3 D9901 trial shows provenge extends survival in patients with advanced prostate cancer. http:\/\/investor.dendreon.com\/ReleaseDetail.cfm?ReleaseID=146750&Header=IR."},{"key":"10.1093\/annonc\/mdj138_bb0070","first-page":"881","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"87","author":"Duffaud","year":"2000","journal-title":"Bull Cancer"},{"key":"10.1093\/annonc\/mdj138_bb0075","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1054\/bjoc.2001.1731","article-title":"Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)","volume":"84","author":"Hauschild","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdj138_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(98)00208-7","article-title":"Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application","volume":"223","author":"Thurner","year":"1999","journal-title":"J Immunol Methods"},{"key":"10.1093\/annonc\/mdj138_bb0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-1759(02)00189-8","article-title":"Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories","volume":"268","author":"Berger","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1093\/annonc\/mdj138_bb0090","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdj138_bb0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj138_bb0100","author":"Food and Drug Administration Center for Drug Evaluation and Research: Oncologic Drugs Advisory Committee. Briefing Material: May 3","year":"2004","journal-title":"AM Session \u2013 Genasense"},{"key":"10.1093\/annonc\/mdj138_bb0105","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1158\/0008-5472.CAN-04-2048","article-title":"International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?","volume":"64","author":"Belardelli","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdj138_bb0110","first-page":"12","article-title":"Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state","volume":"63","author":"de Vries","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdj138_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1479-5876-2-27","article-title":"Evaluation of in vivo labelled dendritic cell migration in cancer patients","volume":"2","author":"Ridolfi","year":"2004","journal-title":"J Transl Med"},{"issue":"11","key":"10.1093\/annonc\/mdj138_bb0120","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/ni1129","article-title":"Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity","author":"Smith","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1093\/annonc\/mdj138_bb0125","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/sim.1296","article-title":"Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems","volume":"21","author":"Pocock","year":"2002","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mdj138_bb0130","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2002.08.072","article-title":"Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome","volume":"20","author":"Sosman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj138_bb0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.0001-2815.2004.00250.x","article-title":"HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma","volume":"64","author":"Luongo","year":"2004","journal-title":"Tissue Antigens"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419575652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419575652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/4\/563\/685418\/mdj138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T03:48:03Z","timestamp":1624420083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419575652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0923753419575652"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdj138","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}